Feraccru to be made available in Wales but not Scotland

Ferric Maltol (Feraccru) -  a treatment for iron deficiency anaemia for people with Crohn's or Colitis - is now available for use within NHS Wales.

The All Wales Therapeutic and Toxicology Centre recently reconsidered their previous decision in 2017 and in November 2022, approved Feraccru for people with Crohn’s and Colitis who have not responded to traditional iron tablets.

The Scottish Medicines Consortium (SMC) have also reconsidered their 2017 decision for Feraccru but have announced that they would not approve this treatment.

We submitted evidence to both organisations and are disappointed in these different decisions. Feraccru will only be available to patients in Scotland through the Peer Approved Clinical System process.

We will continue working to ensure that the difference this - and other new treatments - may make to people with Crohn’s and Colitis, is fully recognised and understood by those making the decisions.

We do this through submissions and consultation responses, based on the evidence provided by people with Crohn’s and Colitis. Where appropriate, we also nominate and support patient experts to present their experience directly to the decision-makers.

If you live in England, Wales, Scotland or Northern Ireland and are experiencing iron deficiency anaemia, speak to your IBD team to find out if Feraccru would be right for you.

Find out more about how we work to increase access to medicines here.